

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel in the order listed for Form Page 2.
Follow the sample format on for each person. (See attached sample). **DO NOT EXCEED FOUR PAGES.**

NAME		POSITION TITLE	
Ian Mark Gralnek		Assistant Professor of Medicine	
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of Minnesota, Minneapolis	B.A.	1984	Physiology
University of Minnesota Medical School, Minneapolis	M.D.	1989	Medicine
UCLA, School of Public Health	M.S.H.S.	1996	Health Services

A. Positions and Honors.**Positions and Employment**

1989 – 1990	Intern, Department of Medicine, Hennepin County Medical Center, Minneapolis, MN
1990 – 1992	Resident, Department of Medicine, Hennepin County Medical Center Minneapolis, MN
1992 – 1993	Chief Medicine Resident, Department of Medicine, Hennepin County Medical Center, Minneapolis, MN
1993 – 1996	Fellow, UCLA Affiliated Training Program in Digestive Diseases, UCLA Center for the Health Sciences, Los Angeles, CA
1996 – 1998	Fellow, West Los Angeles VA Medical Center, Ambulatory Care / Health Services Research.
1996 – 1998	Clinical Instructor, Department of Medicine, Division of Digestive Diseases, UCLA School of Medicine
1998 – Present	Assistant Professor, Department of Medicine, Division of Digestive Diseases, UCLA School of Medicine
1998 – Present	Assistant Professor, Medical Service, Division of Gastroenterology, VA Greater Los Angeles Health Care System
1998 – Present	Section Head, Health Services Research, UCLA Division of Digestive Diseases
2000 – Present	Director, Center for the Study of Digestive Healthcare Quality and Outcomes

Honors

1984	Golden Key National Honor Society
1984	Phi Beta Kappa Honor Society
1994	Gastroenterology Young Clinician Program World Congresses of Gastroenterology
1994	National Research Service Award (NRSA Fellow) UCLA Gastroenterology Training Grant (NIH DK07180-23)
1995	GI Young Investigator, ASGE, AGA, AASLD Young Investigators' Conference on Digestive Diseases
1996	GI Young Investigator, ASGE, AGA, AASLD Young Investigators' Conference on Digestive Diseases
1997	American Digestive Health Foundation / Wilson-Cook Endoscopic Research Scholar Award
1997	CURE: Digestive Diseases Research Center Named New Investigator
1999	VA HSR&D Research Career Development Award
2002	VA HSR&D Advanced Research Career Development Award

B. Selected peer-reviewed publications (in chronological order).

1. **Gralnek IM**, Jensen DM. Cost assessments in the management of variceal bleeding. Clin Liver Dis 1997;1:45-58.
2. **Gralnek IM**, Jensen DM, Kovacs TOG, Jutabha R, Jensen ME, Cheng S, Gornbein J, Freeman M, Machicado GA, Smith J, Sue M, Kominski G. An economic analysis of patients with active arterial peptic ulcer hemorrhage treated with endoscopic heater probe, injection sclerosis, or surgery in a prospective, randomized trial. Gastrointest Endoscopy 1997;46:105-12.
3. Rosen HR, Shackleton CR, Higa L, **Gralnek IM**, Farmer DA, McDiarmid SV, Holt C, Lewin KJ, Busuttill RW, Martin P. OKT3 use is associated with early and severe hepatitis C recurrence and graft loss following liver transplantation. Am J Gastroenterol 1997;92:1453-7.
4. **Gralnek IM**. Health care utilization and economic issues in irritable bowel syndrome. Eur J Surg 1998;583:73-76.

5. Fass R, Fennerty B, Ofman JJ, **Gralnek IM**, Johnson C, Camargo L, Sampliner RE. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain (NCCP). *Gastroenterology* 1998;115:42-49.
6. **Gralnek IM**, Jensen DM, Kovacs TOG, Jutabha R, Jensen ME, Cheng S, Gornbein J, Freeman ML, Machicado GA, Smith J, Sue M. Clinical and economic outcomes of individuals with severe peptic ulcer hemorrhage and non-bleeding visible vessel: an analysis of two prospective clinical trials. *Am J Gastroenterol* 1998;93:2047-56.
7. **Gralnek IM**, Jensen DM, Kovacs TOG, Jutabha R, Gornbein J, Cheng S, King J, Jensen ME. The economic impact of esophageal variceal hemorrhage. Cost-effectiveness implications of endoscopic therapy. *Hepato* 1999;29:44-50.
8. **Gralnek IM**, Liu HH, Shapiro MF, Martin P. The United States liver donor population in the 1990s: A descriptive, population-based comparative study. *Transplantation* 1999;67:1019-23.
9. Fass R, Ofman JJ, **Gralnek IM**, Johnson C, Camargo E, Sampliner RE, Fennerty MB. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. *Arch Intern Med* 1999;159:2161-2168.
10. Ofman JJ, **Gralnek IM**, Udani J, Fass R. The cost-effectiveness of the omeprazole test in non-cardiac chest pain. *Am J Med* 1999;107:219-27.
11. **Gralnek IM**. Procedure specific outcomes assessment: GI bleeding. *Gastrointest Endosc Clin N Am* 1999;9:665-670.
12. **Gralnek IM**, Hays RD, Rosen HR, Keeffe EB, Artinian L, Kim S, Lazarovici D, Jensen DM, Gross J, Busuttill RW, Martin P. Development and evaluation of the liver disease quality of life instrument, LDQOL 1.0. *Am J Gastroenterol* 2000;95:3552-3565.
13. **Gralnek IM**, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. *Gastroenterology* 2000;119:654-660.
14. **Gralnek IM**. Diagnosis and management of gastroesophageal reflux disease in the primary care setting. Can health-related quality of life play a role? *Am J Gastroenterol* 2001;96:S54-S56.
15. **Gralnek IM**. Measuring health-related quality of life in gastroenterology and hepatology: A patient-centered outcome. *Clin Perspect in Gastroenterol* 2001;312-316.
16. **Gralnek IM**, Jensen DM. A potpourri of colonic lesions causing severe hematochezia. *Techniques Gastrointest Endosc* 2001;3:216-220.
17. Dulai GS, **Gralnek IM**, Oei TT, Chang D, Alofaituli G, Gornbein J, Kahn K. Over-utilization of healthcare resources for low-risk patients with acute, non-variceal upper gastrointestinal hemorrhage: A historical cohort study. *Gastrointest Endosc* 2002;55:321-327.
18. Oei TT, Dulai GS, **Gralnek IM**, Chang D, Kilbourne AM, Alofaituli Sale G. Hospital care for low-risk patients with acute, non-variceal upper gastrointestinal hemorrhage: a comparison of neighboring community and tertiary care centers. *Am J Gastroenterol* 2002;97:2271-8.
19. Jensen DM, Kovacs TOG, Jutabha R, Machicado GA, **Gralnek IM**, Savides TJ, Smith J, Lam F, et al. Randomized, controlled trial of medical therapy compared to endoscopic therapy for prevention of recurrent ulcer hemorrhage in patients with non-bleeding adherent clots. *Gastroenterology* 2002;123:407-13.
20. Kanwal F, **Gralnek IM**. Measuring health-related quality of life in gastroenterology and hepatology: Part 1. *Evidence-Based Gastroenterology* 2002;4:128-132.
21. Provenzale D, Ofman JJ, **Gralnek IM**, Rabeneck L, Koff R, McCrory D. Gastroenterologist specialist care is effective compared to care provided by generalists. *Am J Gastroenterol* 2003;98:21-28.
22. Spiegel BMR, Targownik L, Karsan H, Dulai GS, **Gralnek IM**. Endoscopic screening for esophageal varices. Is it ever cost-effective? *Hepatology* 2003;37:366-77.
23. Kanwal F, Dulai GS, Jensen DM, Jutabha R, **Gralnek IM**, Kovacs TOG, Machicado GA. Major stigmata of recent hemorrhage in rectal ulcers in patients with severe hematochezia. *Gastrointest Endosc* 2003;57:462-468.
24. Kanwal F, **Gralnek IM**. Measuring health-related quality of life in gastroenterology and hepatology. Part 2 – What is available? *Evidence-Based Gastroenterology* 2003;4:65-79.
25. Spiegel BMR, Targownik L, Karsan H, Dulai GS, **Gralnek IM**. The cost-effectiveness of COX 2 inhibitors in the treatment of chronic arthritis. *Ann Intern Med* 2003;138:795-806.
26. Spiegel BMR, **Gralnek IM**. Carvedilol or propranolol for variceal prophylaxis? Unconfidence intervals confound the choice. *Evidence-Based Medicine* 2003. (In Press)
27. Targownik LE, **Gralnek IM**, Dulai GS, Oei T, Chang D, Chang M, Bernstein CN. Management of acute non-variceal upper gastrointestinal hemorrhage: comparison of U.S. and Canadian medical centers. *Can J Gastroenterol* 2003. (In Press)
28. Dulai GS, Jensen DM, Kovacs TOG, **Gralnek IM**, Jutabha R. Endoscopic treatment outcomes in watermelon stomach patients with and without portal hypertension. *Endoscopy* 2003. (In Press)

C. Research Support

Ongoing Research Support

Advanced Research Career Development Award Gralnek (PI) 7/1/02 – 6/3/05

VA HSR&D

Establishing a VA Model for Best Practices in the Management of Acute Upper GI Hemorrhage

The goal of this award is to provide advanced research career development in health services research methodologies applied to gastroenterology and hepatology.

Role: PI

IIR 01-191-1 Gralnek (PI)

10/1/02 – 9/30/05

VA HSR&D

Establishing a VA Model for Best Practices in the Management of Acute Upper GI Hemorrhage,

The goal of this project is to establish “best practices” in the management of acute upper gastrointestinal hemorrhage.

Role: PI

CRS 02-162 Gralnek (PI)

7/1/02 – 12/31/04

VA HSR&D

Colorectal Cancer Screening Assessment and Surveillance Data System

The goal of this project is to evaluate colorectal cancer screening and surveillance practices at VA centers across the United States.

Role: Site PI

Gralnek (PI)

10/1/02 – 9/30/03

Pharmacia Pharmaceuticals

Double-Blind, Placebo-Controlled, Randomized 2 Week Study, Comparing Small Bowel Injury Associated with Celecoxib (200 mg BID) with Naproxen (500 mg BID) and Omeprazole (20 mg QD)

The goal of this project is to evaluate small bowel injury associated with use of a COX II inhibitor (Celecoxib) versus a non-specific NSAID (Naproxen) + a proton pump inhibitor (Omeprazole) versus placebo.

Role: Site Co-PI

Completed Research Support

TAP Pharmaceuticals

7/1/02 – 6/30/03

Inappropriate Use and Substitution of OTC H2RAs for Physician Care

The goal of this study is to describe the demographic characteristics of the population purchasing OTC H2RAs from community retail pharmacies, determine the rates and predictors of inappropriate OTC H2RA utilization in this population, and determine the rates and predictors of substitution of OTC H2RAs for physician care.

Role: Co-Investigator

Research Career Development Award Gralnek (PI)

7/1/99 – 6/30/02

VA HSR&D

Measuring Process and Outcomes of Care in VA Patients with Chronic Liver Disease

The goal of this award is to provide entry-level research career development in health services research methodologies applied to gastroenterology and hepatology.

Role: PI

Gralnek (PI)

7/1/01 – 6/30/02

American College of Gastroenterology

Determinants of Provider Behavior and Factors Influencing the Process of Healthcare Delivery to Patients with “Low-Risk” Non-Variceal Upper Gastrointestinal Hemorrhage

This study will evaluate factors influencing the process of care for patients with “low-risk” UGI hemorrhage.

Specifically, we will conduct focus groups of emergency medicine physicians, primary care providers, gastroenterologists, hospital administrators, and patients with a history of UGI hemorrhage to attain this information.

Role: PI

Principal Investigator/Program Director (Last, First, Middle):

Gralnek (PI)

7/1/01 – 6/30/02

Janssen-Eisai Pharmaceutic

Determinants of Provider Behavior and Factors Influencing the Process of Healthcare Delivery to Patients with “Low-Risk” Non-Variceal Upper Gastrointestinal Hemorrhage

This study will evaluate factors influencing the process of care for patients with “low-risk” UGI hemorrhage.

Specifically, we will conduct focus groups of emergency medicine physicians, primary care providers, gastroenterologists, hospital administrators, and patients with a history of UGI hemorrhage to attain this information.

Role: PI

Gralnek (PI)

1/1/00 – 12/31/00

AMGEN Pharmaceuticals

Pilot Testing of an Instrument to Assess Health-Related Quality of Life Among Persons with Hepatitis C, the HCV-QOL

This study will develop and pilot test a health-related quality of life instrument for persons with chronic hepatitis C virus.

Role: Co-PI